STRM.BIO
Fulfilling the promise of gene therapy.
Fulfilling the promise of gene therapy.
STRM.BIO is a Boston-based biotechnology startup founded in 2019, with a goal to revolutionize gene therapy using extracellular vesicles (EVs). Backed by venture capital, notably including a grant investment from the Bill & Melinda Gates Foundation in October 2023, this pre-clinical company is dedicated to making gene therapy more accessible and effective. Unlike traditional viral carriers, EVs offer natural nucleic acid and protein delivery with specific targeting and low immunogenicity, providing an ideal platform for gene therapy innovation. STRM.BIO's pioneering EV platform is poised to unlock a new class of therapeutics, potentially addressing rare diseases and enhancing existing treatment approaches. The company's commitment to democratizing gene therapy and bringing hope to patients worldwide is evident in their vision to recruit exceptional talents to turn this vision into reality.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | Unknown | 1 |
|
03 Oct 2023 |
| Seed Round | Unknown | 1 |
|
11 May 2023 |
| Grant | $2.10M | 1 |
-logo.jpg){kind=logo}
|
26 Jul 2022 |
No recent news or press coverage available for STRM.BIO.
We care about your data, and we'd love to use cookies make your experience better.